NovaBay Pharmaceuticals Files S-1 for Stock Offering

TL;DR

NovaBay just filed an S-1 for a stock offering - watch for details on price and shares!

AI Summary

NovaBay Pharmaceuticals, Inc. filed an S-1 registration statement on June 20, 2024, to register an unspecified number of shares of its common stock. The company, incorporated in Delaware, is based in Emeryville, CA, and operates in the pharmaceutical preparations sector. This filing indicates a potential offering of securities to the public, though specific details on the offering size and price are not yet disclosed.

Why It Matters

This S-1 filing signals NovaBay Pharmaceuticals' intent to raise capital through a public stock offering, which could fund future research, development, or expansion efforts.

Risk Assessment

Risk Level: medium — S-1 filings indicate a company is seeking to raise capital, which can be a positive sign, but the lack of specific offering details and the inherent risks of the pharmaceutical industry warrant a medium risk assessment.

Key Numbers

• 333-280363 — SEC File Number (Identifies the specific SEC registration for this filing.)
• 2834 — SIC Code (Indicates the company operates in the Pharmaceutical Preparations industry.)

Key Players & Entities

• NovaBay Pharmaceuticals, Inc. (company) — Registrant
• 2000 Powell Street, Suite 1150 Emeryville, CA 94608 (location) — Principal Executive Offices
• Justin M. Hall (person) — Chief Executive Officer and General Counsel
• Squire Patton Boggs (US) LLP (company) — Legal Counsel
• Abby E. Brown (person) — Legal Counsel

FAQ

Key Financial Figures

• $0.01 — he " Company ") common stock, par value $0.01 per share (the " Common Stock "), issua
• $2.30 — f our Common Stock on June 18, 2024 was $2.30 per share. We are a "smaller reporting
• $8 — n Stock, at a reduced exercise price of $8.75, which resulted in cash proceeds to
• $0.6 m — hich resulted in cash proceeds to us of $0.6 million, before deducting warrant reprice
• $525,000 — t have an aggregate principal amount of $525,000 or will be convertible into an aggregat
• $2 — n Stock, at a reduced exercise price of $2.50, which resulted in cash proceeds to
• $225,953, b — hich resulted in cash proceeds to us of $225,953, before deducting warrant reprice agent fe

Filing Documents

• nby20240619_s1.htm (S-1) — 501KB
• ex_690586.htm (EX-5.1) — 17KB
• ex_690762.htm (EX-23.1) — 3KB
• ex_690763.htm (EX-FILING FEES) — 22KB
• ex_690586img001.jpg (GRAPHIC) — 4KB
• nby20240619_s1img001.jpg (GRAPHIC) — 5KB
• nby20240619_s1img002.jpg (GRAPHIC) — 7KB
• 0001437749-24-020830.txt ( ) — 566KB

Risk Factors

Risk Factors 8 Special Note Regarding Forward-Looking Statements 19

Use of Proceeds

Use of Proceeds 20 Market for our Common Stock 21 Dividend Policy 21 Principal Stockholders 22

Description of Capital Stock

Description of Capital Stock 23 Selling Stockholders 27 Plan of Distribution 30 Legal Matters 32 Experts 32 Where You Can Find More Information 32 Incorporation of Certain Documents by Reference 32 ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 filed with the U.S. Securities and Exchange Commission (the " SEC "), using a "shelf" registration process. By using a shelf registration statement, the Selling Stockholders may sell up to 298,355 shares of Common Stock received upon exercise or conversion (as the case may be) of the Warrants or the Unsecured Convertible Notes, from time to time in one or more offerings as described in this prospectus. We will not receive any proceeds from the sale of the Shares by the Selling Stockholders. However, upon any cash exercise of the Warrants by the Selling Stockholders, we will receive cash proceeds per share equal to the exercise price of such Warrants. If the Warrants are exercised in a cashless exercise, we will not receive any proceeds from the exercise of the Warrants. Upon the conversion of any portion of the Unsecured Convertible Notes, the amount of debt outstanding and owed by us will be reduced by the amount of the Unsecured Convertible Notes that was converted into shares of Common Stock. We may also file a prospectus supplement or post-effective amendment to the registration statement of which this prospectus forms a part, which may contain material information relating to this offering. The prospectus supplement or post-effective amendment may also add, update or change information contained in this prospectus with respect to the offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or post-effective amendment, you should rely on the prospectus supplement or post-effective amendment, as applicable. As permitted by the rules and regulations of the SEC, the registration statement filed by us inc

View Full Filing

View this S-1 filing on SEC EDGAR